

Gustave Roussy

Service de Biostatistique et d'Epidémiologie / Biostatistics and Epidemiology Department

Publications 2014

1. Fumagalli D, Blanchet-Cohen A, Brown D, Desmedt C, Gacquer D, Michiels S, Rothé F, Majaj S, Salgado R, Larsimont D, Ignatiadis M, Maetens M, Piccart M, Detours V, Sotiriou C, Haibe-Kains B. Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology. *BMC Genomics* 2014; 15:1008.
2. Bonastre J, Marguet S, Lueza B, Michiels S, Delalogue S, Saghatchian M. Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer. *J Clin Oncol* 2014; 32:3513-9.
3. Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, Zhang Z, Lapouble E, Grossetête-Lalami S, Rusch M, Reynaud S, Rio-Frio T, Hedlund E, Wu G, Chen X, Pierron G, Oberlin O, Zaidi S, Lemmon G, Gupta P, Vadodaria B, Easton J, Gut M, Ding L, Mardis ER, Wilson RK, Shurtleff S, Laurence V, Michon J, Marec-Bérard P, Gut I, Downing J, Dyer M, Zhang J, Delattre O, St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project and the International Cancer Genome Consortium. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. *Cancer Discov* 2014; 4:1342-53.
4. Verlingue L, Koscielny S, Ferté C. Should we resist to including tumour growth patterns in Response Evaluation Criteria in Solid Tumours evaluation? (Response to Litière et al.). *Eur J Cancer* 2014; 50:2887-8.
5. Ternès N, Arnedos M, Koscielny S, Michiels S, Lanoy E. Statistical methods applied to omics data: predicting response to neoadjuvant therapy in breast cancer. *Curr Opin Oncol* 2014; 26:576-83.
6. Rotolo F, Dunant A, Le Chevalier T, Pignon JP, Arriagada R, IALT Collaborative Group. Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach. *Ann Oncol* 2014; 25:2162-6.
7. Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart M, Sotiriou C, Ignatiadis M. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. *Ann Oncol* 2014; 25:1959-65.
8. Lamora A, Talbot J, Bougras G, Amiaud J, Leduc M, Chesneau J, Taurelle J, Stresing V, Le Deley MC, Heymann MF, Heymann D, Redini F, Verrecchia F. Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma. *Clin Cancer Res* 2014; 20:5097-112.
9. Hill C. [Author's response to the letter on the article: "Breast cancer screening"]. *Presse Med* 2014; 43:1308-10.
10. Burdett S, Rydzewska LH, Tierney JF, Auperin A, Pignon JP, Le Pechoux C, Le Chevalier T, van Meerbeeck J. Preoperative chemotherapy for non-small-cell lung cancer--authors' reply. *Lancet* 2014; 384:233.
11. Le Pechoux C, Arriagada R, Pignon JP. Need for new powered trials to assess the role of post-operative radiotherapy for stage III non-small cell lung cancer. *Radiother Oncol* 2014; 112:314-5.
12. Girinsky T, Aupérin A, Ribrag V, Elleuch M, Fermé C, Bonniaud G, Ruelle C, Alberini JL, Celebic A, Edeline V. Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients. *Int J Radiat Oncol Biol Phys* 2014; 89:1047-52.
13. Ducreux M, Giovannini M, Baey C, Llacer C, Bennouna J, Adenis A, Peiffert D, Mornex F, Abbas M, Boige V, Pignon JP, Conroy T, Cellier P, Juzyna B, Viret F. Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial. *Dig Liver Dis* 2014; 46:950-5.
14. Lassau N, Bonastre J, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Coiffier B, Benastou B, Koscielny S. Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the

- French multicenter support for innovative and expensive techniques study. *Invest Radiol* 2014; 49:794-800.
15. Le Deley MC,Paulussen M,Lewis I,Brennan B,Ranft A,Whelan J,Le Teuff G,Michon J,Ladenstein R,Marec-Bérard P,van den Berg H,Hjorth L,Wheatley K,Judson I,Juergens H,Craft A,Oberlin O,Dirksen U. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. *J Clin Oncol* 2014; 32:2440-8.
 16. Gattolliat CH,Le Teuff G,Combaret V,Mussard E,Valteau-Couanet D,Busson P,Bénard J,Douc-Rasy S. Expression of two parental imprinted miRNAs improves the risk stratification of neuroblastoma patients. *Cancer Med* 2014; 3:998-1009.
 17. Lueza B,Le Péchoux C,Pignon JP. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. *Ann Oncol* 2014; 25:1865-6.
 18. Caniglia EC,Cain LE,Justice A,Tate J,Logan R,Sabin C,Winston A,van Sighem A,Miro JM,Podzamczar D,Olson A,Arribas JR,Moreno S,Meyer L,del Romero J,Dabis F,Bucher HC,Wandeler G,Vourli G,Skoutelis A,Lanoy E,Gasnault J,Costagliola D,Hernán MA,HIV-CAUSAL Collaboration. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. *Neurology* 2014; 83:134-41.
 19. Rotolo F,Michiels S. Testing the treatment effect on competing causes of death in oncology clinical trials. *BMC Med Res Methodol* 2014; 14:72.
 20. Raphael J,Le Teuff G,Hollebecque A,Massard C,Bahleda R,Margery J,Besse B,Soria JC,Planchard D. Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution. *Lung Cancer* 2014; 85:251-7.
 21. Deschamps F,Farouil G,Ternes N,Gaudin A,Hakime A,Tselikas L,Teritehau C,Baudin E,Auperin A,de Baere T. Thermal ablation techniques: a curative treatment of bone metastases in selected patients? *Eur Radiol* 2014; 24:1971-80.
 22. Malka D,Cervera P,Foulon S,Trarbach T,de la Fouchardière C,Boucher E,Fartoux L,Faivre S,Blanc JF,Viret F,Assenat E,Seufferlein T,Herrmann T,Grenier J,Hammel P,Dollinger M,André T,Hahn P,Heinemann V,Rousseau V,Ducreux M,Pignon JP,Wendum D,Rosmorduc O,Greten TF,BINGO investigators. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. *Lancet Oncol* 2014; 15:819-28.
 23. Hill C. [Cancer: screening inconsistencies]. *Rev Prat* 2014; 64:307-9.
 24. Al Nakouzi N,Le Moulec S,Albigès L,Wang C,Beuzeboc P,Gross-Goupil M,de La Motte Rouge T,Guillot A,Gajda D,Massard C,Gleave M,Fizazi K,Loriot Y. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. *Eur Urol* 2014; :.
 25. Ferté C,Koscielny S,Soria JC. TGR analysis in phase I clinical trials--response. *Clin Cancer Res* 2014; 20:2497.
 26. Ignatiadis M,Riethdorf S,Bidard FC,Vaucher I,Khazour M,Rothé F,Metallo J,Rouas G,Payne RE,Coombes R,Teufel I,Andergassen U,Apostolaki S,Politaki E,Mavroudis D,Bessi S,Pestrin M,Di Leo A,Campion M,Reinholz M,Perez E,Piccart M,Borgen E,Naume B,Jimenez J,Aura C,Zorzino L,Cassatella M,Sandri M,Mostert B,Sleijfer S,Kraan J,Janni W,Fehm T,Rack B,Terstappen L,Repollet M,Pierga JY,Miller C,Sotiriou C,Michiels S,Pantel K. International study on inter-reader variability for circulating tumor cells in breast cancer. *Breast Cancer Res* 2014; 16:R43.
 27. Ezratty V,Guillosoy G,Neukirch C,Dehoux M,Koscielny S,Bonay M,Cabanes PA,Samet JM,Mure P,Roport L,Tokarek S,Lambrozo J,Aubier M. Repeated nitrogen dioxide exposures and eosinophilic airway inflammation in asthmatics: a randomized crossover study. *Environ Health Perspect* 2014; 122:850-5.
 28. Uzan C,Nikpayam M,Ribassin-Majed L,Gouy S,Bendifallah S,Cortez A,Rey A,Duvillard P,Darai E,Morice P. Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments. *Ann Oncol* 2014; 25:1312-9.
 29. Dias MM,Pignon JP,Karapetis CS,Boige V,Glimelius B,Kweekel DM,Lara PN,Laurent-Puig P,Martinez-Balibrea E,Páez D,Punt CJ,Redman MW,Toffoli G,Wadelius M,McKinnon RA,Sorich

- MJ. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. *Pharmacogenomics J* 2014; 14:424-31.
30. Hill C. [Breast cancer screening]. *Presse Med* 2014; 43:501-9.
 31. Hill C, Fournier A. [THM: many unknowns before asserting that the balance is in favor of a profit!]. *Rev Prat* 2014; 64:162-4.
 32. Haddy N, Tartier L, Koscielny S, Adadj E, Rubino C, Brugières L, Pacquement H, Diallo I, de Vathaire F, Averbeck D, Hall J, Benhamou S. Repair of ionizing radiation-induced DNA damage and risk of second cancer in childhood cancer survivors. *Carcinogenesis* 2014; 35:1745-9.
 33. Spiegel A, Paillard C, Ducassou S, Perel Y, Plantaz D, Strullu M, Eischen A, Lutz P, Lamant L, Le Deley MC, Brugières L. Paediatric anaplastic large cell lymphoma with leukaemic presentation in children: a report of nine French cases. *Br J Haematol* 2014; 165:545-51.
 34. Pasqualini C, Minard-Colin V, Saada V, Lamant L, Delsol G, Patte C, Le Deley MC, Valteau-Couanet D, Brugières L. Clinical analysis and prognostic significance of haemophagocytic lymphohistiocytosis-associated anaplastic large cell lymphoma in children. *Br J Haematol* 2014; .
 35. Lanoy E. [Epidemiology, risk factor and screening for melanoma and other skin cancers]. *Rev Prat* 2014; 64:31-6.
 36. Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. *Lancet Oncol* 2014; 15:406-14.
 37. Girinsky T, M'Kacher R, Lessard N, Koscielny S, Elfassy E, Raoux F, Carde P, Santos MD, Margainaud JP, Sabatier L, Ghalibafian M, Paul JF. Prospective coronary heart disease screening in asymptomatic Hodgkin lymphoma patients using coronary computed tomography angiography: results and risk factor analysis. *Int J Radiat Oncol Biol Phys* 2014; 89:59-66.
 38. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Ann Oncol* 2014; 25:1544-50.
 39. Ianculescu V, Ciolovan LM, Dunant A, Vielh P, Mazouni C, Delaloge S, Dromain C, Blidaru A, Balleyguier C. Added value of Virtual Touch IQ shear wave elastography in the ultrasound assessment of breast lesions. *Eur J Radiol* 2014; 83:773-7.
 40. Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. *J Clin Oncol* 2014; 32:1031-9.
 41. Goéré D, Gras-Chaput N, Aupérin A, Flament C, Mariette C, Glehen O, Zitvogel L, Elias D. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. *BMC Cancer* 2014; 14:148.
 42. Ma X, Rousseau V, Sun H, Lantuejoul S, Filipits M, Pirker R, Popper H, Mendiboure J, Vataire AL, Le Chevalier T, Soria JC, Brambilla E, Dunant A, Hainaut P, IALT-Bio working group. Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. *Mol Oncol* 2014; 8:555-64.
 43. Macerelli M, Caramella C, Faivre L, Besse B, Planchard D, Polo V, Ngo Camus M, Celebic A, Koubi-Pick V, Lacroix L, Pignon JP, Soria JC. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)? *Lung Cancer* 2014; 83:383-8.
 44. Mauguen A, Collette S, Pignon JP, Rondeau V. Reply to 'interpretation of concordance measures for clustered data'. *Stat Med* 2014; 33:717-8.

45. Antoun S, Lanoy E, Albiges-Sauvin L, Escudier B. Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma. *Expert Rev Anticancer Ther* 2014; 14:279-88.
46. Janin M, Mylonas E, Saada V, Micol JB, Renneville A, Quivoron C, Koscielny S, Scourzic L, Forget S, Pautas C, Caillet D, Preudhomme C, Dombret H, Berthon C, Barouki R, Rabier D, Auger N, Griscelli F, Chachaty E, Leclercq E, Courtier MH, Bennaceur-Griscelli A, Solary E, Bernard OA, Penard-Lacronique V, Ottolenghi C, de Botton S. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. *J Clin Oncol* 2014; 32:297-305.
47. Cousin S, Hollebecque A, Koscielny S, Mir O, Varga A, Baracos VE, Soria JC, Antoun S. Low skeletal muscle is associated with toxicity in patients included in phase I trials. *Invest New Drugs* 2014; 32:382-7.
48. Corcos G, Dbjay J, Mastier C, Leon S, Auperin A, De Baere T, Deschamps F. Cement leakage in percutaneous vertebroplasty for spinal metastases: a retrospective evaluation of incidence and risk factors. *Spine (Phila Pa 1976)* 2014; 39:E332-8.
49. Blanchard P, Bourhis J, Pignon JP. Reply to D. Tural et al. *J Clin Oncol* 2014; 32:259-60.
50. Ferte C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, Balheda R, Bot B, Gomez-Roca C, Dromain C, Ammari S, Soria JC. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. *Clin Cancer Res* 2014; 20:246-52.
51. Romero AI, Chaput N, Poirier-Colame V, Rusakiewicz S, Jacquelot N, Chaba K, Mortier E, Jacques Y, Caillat-Zucman S, Flament C, Caignard A, Messaoudene M, Auperin A, Vielh P, Dessen P, Porta C, Mateus C, Ayyoub M, Valmori D, Eggermont A, Robert C, Zitvogel L. Regulation of CD4(+)/NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15R α and NKG2D triggering. *Cancer Res* 2014; 74:68-80.
52. Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F, Solassol J, Denis MG, Cayre A, Nanni-Metellus I, Olschwang S, Lizard S, Piard F, Pretet JL, de Fraipont F, Bièche I, de Cremoux P, Rouquette I, Bringuier PP, Mosser J, Legrain M, Voegeli AC, Saulnier P, Morin F, Pignon JP, Zalzman G, Cadranet J. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms. *J Mol Diagn* 2014; 16:45-55.
53. Melkane AE, Mirghani H, Auperin A, Saulnier P, Lacroix L, Vielh P, Casiraghi O, Griscelli F, Temam S. HPV-related oropharyngeal squamous cell carcinomas: a comparison between three diagnostic approaches. *Am J Otolaryngol* 2014; 35:25-32.
54. Di Giannatale A, Dias-Gastellier N, Devos A, Mc Hugh K, Boubaker A, Courbon F, Verschuur A, Ducassou S, Malekzadeh K, Casanova M, Amoroso L, Chastagner P, Zwaan CM, Munzer C, Aerts I, Landman-Parker J, Riccardi R, Le Deley MC, Geoerger B, Rubie H. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. *Eur J Cancer* 2014; 50:170-7.
55. Ferte C, Koscielny S, Albiges L, Rocher L, Soria JC, Iacovelli R, Loriot Y, Fizazi K, Escudier B. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. *Eur Urol* 2014; 65:713-20.
56. Valteau-Couanet D, Le Deley MC, Bergeron C, Ducassou S, Michon J, Rubie H, Le Teuff G, Coze C, Plantaz D, Sirvent N, Bouzy J, Chastagner P, Hartmann O. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. *Pediatr Blood Cancer* 2014; 61:977-81.
57. Lervat C, Auperin A, Patte C, Méchinaud F, Leverger G, Nelken B, Bertrand Y, Baruchel A, Coze C, Munzer M, Lacombe MJ, Bergeron C. Head and neck presentations of B-NHL and B-AL in children/adolescents: experience of the LMB89 study. *Pediatr Blood Cancer* 2014; 61:473-8.
58. Melkane AE, Auperin A, Saulnier P, Lacroix L, Vielh P, Casiraghi O, Msakni I, Drusch F, Temam S. Human papillomavirus prevalence and prognostic implication in oropharyngeal squamous cell carcinomas. *Head Neck* 2014; 36:257-65.

59. Mirghani H, Mortuaire G, Armas GL, Hartl D, Aupérin A, El Bedoui S, Chevalier D, Lefebvre JL. Sinonasal cancer: Analysis of oncological failures in 156 consecutive cases. *Head Neck* 2014; 36:667-74.
60. Hakimé A, Le Cesne A, Deschamps F, Farouil G, Boudabous S, Aupérin A, Domont J, Debaere T. A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors. *Cardiovasc Intervent Radiol* 2014; 37:132-9.
61. Ribassin-Majed L, Lounes R, Clemençon S. Deterministic modelling for transmission of Human Papillomavirus 6/11: impact of vaccination. *Math Med Biol* 2014; 31:125-49.
62. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF, PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *JAMA* 2015; 313:1657-65.
63. Vale CL, Ryzewska LH, Rovers MM, Emberson JR, Gueyffier F, Stewart LA, Cochrane IPD Meta-analysis Methods Group. Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. *BMJ* 2015; 350:h1088.
64. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. *N Engl J Med* 2014; 371:203-12.
65. EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet* 2014; 383:2127-35.
66. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. *Lancet* 2014; 383:1561-71.
67. Gupta RK, Goodall RL, Ranopa M, Kityo C, Munderi P, Lyagoba F, Mugarura L, Gilks CF, Kaleebu P, Pillay D, DART Virology Group and Trial Team. High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. *Clin Infect Dis* 2014; 58:1023-6.
68. Bellocq JP, Luporsi E, Barrière J, Bonastre J, Chetritt J, Le Corroller AG, de Crémoux P, Fina F, Gauchez AS, Kassab-Chahmi D, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V. [uPA/PAI-1, Oncotype DX™, MammaPrint®]. Prognosis and predictive values for clinical utility in breast cancer management]. *Ann Pathol.* 2014 Oct;34(5):349-51.
69. Bonastre J, Marguet S, Lueza B, Michiels S, Delalogue S, Saghatchian M. Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer. *J Clin Oncol.* 2014 Nov 1;32(31):3513-9.
70. Lassau N, Bonastre J, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Coiffier B, Benastou B, Koscielny S. Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors: The French Multicenter Support for Innovative and Expensive Techniques Study. *Invest Radiol.* 2014 Dec;49(12):794-800.
71. Bonastre J, Chevalier J, Van der Laan C, Delibes M, De Pouvourville G. Access to innovation: is there a difference in the use of expensive anticancer drugs between French hospitals? *Health Policy.* 2014 Jun;116(2-3):162-9.
72. Mamelie E, Borget I, Leboulleux S, Mirghani H, Suárez C, Pellitteri PK, Shaha AR, Hamoir M, Robbins KT, Khafif A, Rodrigo JP, Silver CE, Rinaldo A, Ferlito A, Hartl DM. Impact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a review. *Eur Arch Otorhinolaryngol* 2014
73. Levy A, Borget I, Bahri M, Arnedos M, Rivin E, Vielh P, Balleyguier C, Rimareix F, Bourgier C. Loco-regional control after neo-adjuvant chemotherapy and conservative treatment for locally advanced breast cancer patients. *Breast J* 2014; 20: 381-7
74. Desplanques JY, Burlacu R, Poinsignon V, BouSSION H, Borget I, Wyplosz B, de Botton S, Billaud E, Chachaty E, Gachot B, Netzer F, Micol JB. Factors influencing posaconazole plasmatic

- concentrations in patients presenting with acute myeloid leukemia. *Medecine et maladies infectieuses. Med Mal Infect.* 2014 Apr;44(4):174-9
75. Hartl DM, Al Ghuzlan A, Borget I, Leboulleux S, Mirghani H, Schlumberger M. Prophylactic level II neck dissection guided by frozen section for clinically node-negative papillary thyroid carcinoma: is it useful? *World journal of surgery.* 2014;38(3):667-72.
76. Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, Deandreis D, Borget I, Lorient C, Chougnet C, Letouze E, Young J, Amar L, Bertherat J, Libe R, Dumont F, Deschamps F, Schlumberger M, Gimenez-Roqueplo AP, Baudin E. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. *Int J Cancer.* 2014 Dec 1;135(11):2711-20.
77. Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudet AL, Do Cao C, Chougnet CN, Leboulleux S, Baudin E, Schlumberger M, de la Fouchardiere C. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. *European journal of endocrinology.* 2014;170(4):575-82.
78. Chouaid C, Borget I, Vergnenegre A. Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies? *J Clin Oncol* 2014; 32: 3577.
79. Borget I, Antoun S, Chachaty E, Gachot B, Alibay A, Di Palma M, Merad M. Modalités de prise en charge des neutropénies fébriles chez les patients traités pour une néoplasie solide dans le service d'urgence de cancérologie Gustave-Roussy et leurs impacts économiques. *Bull Cancer* 2014 ;101 : 925-31.
80. Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaid C, IFCT-GFPC investigators. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. *BMC Cancer* 2014; 14: 953
81. Drubay D, Ancelet S, Acker A, Kreuzer M, Laurier D, Rage E. Kidney cancer mortality and ionizing radiation among French and German uranium miners. *Radiation and Environmental Biophysics.* 2014;53(3):505-13. doi: 10.1007/s00411-014-0547-4. Epub 2014 May 24.
82. C. Lévy, D. Allouache, J. Lacroix, A. E. Dugué, S. Supiot, M. Campone, M. Mahe, S. Kichou, M. Leheurteur, C. Hanzen, V. Dieras, Y. Kirova, F. Campana, E. Le Rhun, L. Gras, T. Bachelot, M.-P. Sunyach, I. Hrab, J. Geffrelot, K. Gunzer, J.-M. Constans, J.-M. Grellard, B. Clarisse, and X. Paoletti, Editor's Choice: REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours, *Ann Oncol*, (2014), 25 (12): 2351-2356.
83. Paoletti X, Le Tourneau C, Verweij J, Siu LL, Seymour L, Postel-Vinay S, Collette L, Rizzo E, Ivy P, Olmos D, Massard C, Lacombe D, Kaye SB, Soria JC ; Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey. *Eur J Cancer.* 2014 Aug;50(12):2050-6.
84. Postel-Vinay S, Collette L, Paoletti X, Rizzo E, Massard C, Olmos D, Fowst C, Levy B, Mancini P, Lacombe D, Ivy P, Seymour L, Le Tourneau C, Siu LL, Kaye SB, Verweij J, Soria JC ; Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study, *Eur J Cancer.* 2014 Aug;50(12):2040-9.
85. Le Tourneau C, Paoletti X, Coquan E, Sablin MP, Zoubir M, Tannock IF. Critical Evaluation of Disease Stabilization as a Measure of Activity of Systemic Therapy: Lessons From Trials With Arms in Which Patients Do Not Receive Active Treatment. *J Clin Oncol.* 2014 Jan 20;32(3):260-3.